ANTIRETROVIRAL THERAPY AND INTERRUPTION OF HIV PERINATAL TRANSMISSION (Q57953906)

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Tran

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Progress in prevention of perinatal HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Detection of maternofetal transfusion by placental alkaline phosphatase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Breastfeeding and vertical transmission of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Mother-child HIV-1 transmission: Timing and determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Global burden of the HIV pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Developmental pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Overview of the potential role of vitamin A in mother-to-child transmission of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Mother to child transmission of zidovudine-resistant HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

The effect of maternal viral load on the risk of perinatal transmission of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021

Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8561%2805%2970013-8

7 January 2021